137 related articles for article (PubMed ID: 1476811)
21. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 immunoreactivity in meningiomas--determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67.
Madsen C; Schrøder HD
Clin Neuropathol; 1997; 16(3):137-42. PubMed ID: 9197938
[TBL] [Abstract][Full Text] [Related]
23. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
[TBL] [Abstract][Full Text] [Related]
24. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
[TBL] [Abstract][Full Text] [Related]
25. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
26. Cell kinetics of human brain tumors: in vivo study with bromodeoxyuridine and flow cytometry.
Danova M; Riccardi A; Gaetani P; Wilson GD; Mazzini G; Brugnatelli S; Buttini R; Butti G; Ucci G; Paoletti P
Eur J Cancer Clin Oncol; 1988 May; 24(5):873-80. PubMed ID: 3169092
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of 201Tl SPECT in patients with glioma: a comparative study with histological diagnosis, clinical feature and proliferative activity].
Oriuchi N; Tamura M; Shibazaki T; Inoue T; Watanabe N; Tateno M; Tomiyoshi K; Hirano T; Igarashi H; Endo K
Kaku Igaku; 1991 Nov; 28(11):1263-71. PubMed ID: 1770641
[TBL] [Abstract][Full Text] [Related]
28. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer.
Bourhis J; Wilson G; Wibault P; Janot F; Bosq J; Armand JP; Luboinski B; Malaise EP; Eschwege F
Laryngoscope; 1994 Apr; 104(4):468-72. PubMed ID: 8164487
[TBL] [Abstract][Full Text] [Related]
29. [Immunohistochemical results obtained with bromodeoxy uridine (BUdR) labelled tumors of the head and neck].
Radner H; Kärcher H
Dtsch Z Mund Kiefer Gesichtschir; 1990; 14(2):116-21. PubMed ID: 2102412
[TBL] [Abstract][Full Text] [Related]
30. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography elucidates transport system and tumor proliferation in meningiomas.
Murakami M; Imahori Y; Kimura S; Tatsuzawa K; Ohwada K; Inoue Y; Sasajima H; Mineura K
Oncol Rep; 2005 Oct; 14(4):853-9. PubMed ID: 16142342
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine.
Raza A; Alvi S; Broady-Robinson L; Showel M; Cartlidge J; Mundle SD; Shetty VT; Borok RZ; Dar SE; Chopra HK; Span L; Parcharidou A; Hines C; Gezer S; Venugopal P; Loew J; Showel J; Alston D; Hernandez B; Rifkin S; Robin E; Shah R; Gregory SA
Exp Hematol; 1997 Jun; 25(6):530-5. PubMed ID: 9197332
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma.
Arrieta O; Garcia E; Guevara P; Garcia-Navarrete R; Ondarza R; Rembao D; Sotelo J
Cancer; 2002 Jun; 94(12):3210-8. PubMed ID: 12115353
[TBL] [Abstract][Full Text] [Related]
34. Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Davis RL
Cancer; 1986 Oct; 58(7):1466-72. PubMed ID: 2427189
[TBL] [Abstract][Full Text] [Related]
35. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
36. Kinetic analysis of glucose metabolism by FDG-PET versus proliferation index of Ki-67 in meningiomas--comparison with gliomas.
Tsuyuguchi N
Osaka City Med J; 1997 Dec; 43(2):209-23. PubMed ID: 9540343
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
38. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
39. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
